Zensar Q1 FY27: Modest growth, BFSI strength, and a margin reset around a large deal

Zensar Technologies began FY27 with a small step up in revenue and a noticeable step down in profitability. For the quarter ended June 30, 2026, consolidated revenue was $159.5 million, up 1.1 percent quarter-on-quarter in constant currency terms. In reported dollars, revenue was up 0.7 percent sequentially. In INR terms, revenue was INR 15,083 million, up 4.0 percent QoQ and 8.9 percent year-on-year.

The more important shift this quarter was on margins. EBITDA margin fell to 14.6 percent from 16.1 percent in Q4 FY26. PAT margin dropped to 12.2 percent, down 220 basis points sequentially. Management tied the margin decline mainly to transition and early-stage execution costs for a large deal, along with higher travel, visa and training expenses.

What drove growth: BFSI did the heavy lifting

The quarter was defined by one clear contributor. Banking and Financial Services delivered 8.3 percent QoQ constant currency growth and expanded its revenue share to 48.8 percent. The CEO confirmed that the large deal that started execution in mid-February contributed to BFSI growth, but the company did not quantify the contribution. He also stated that BFSI grew even without counting the large deal.

Outside BFSI, performance was mixed to weak. Telecommunications, Media and Technology declined 9.1 percent QoQ in constant currency and was down 28.0 percent year-on-year. Manufacturing and Consumer Services declined 2.3 percent QoQ. Healthcare and Life Sciences declined 3.8 percent QoQ.

Management commentary offered a few specific cues. In TMT, the CEO said performance is better if the largest client is excluded, implying a client-specific drag. In Healthcare and Life Sciences, he cited portfolio and client-specific issues, including consolidation at one or two clients where Zensar was consolidated out. He also mentioned that a slowdown in FDA decision-making and adverse FDA outcomes affected some biotech-focused clients.

Geographically, the US remained the anchor at 66.2 percent of revenue, with 2.5 percent QoQ constant currency growth. Europe was 21.5 percent of revenue and declined 1.4 percent QoQ, although it grew 3.0 percent year-on-year in constant currency. Africa was 12.3 percent and declined 1.4 percent QoQ.

Margin pressure explained: large deal transition and cost mix

The company provided a clear narrative for the sequential margin decline. The CFO described two key drivers: pre-staffing and transition for the large deal setup, and an increase in other direct costs including travel, visa and training. The investor deck’s EBITDA walk attributes minus 2.0 percentage points to the large deal impact and minus 1.5 percentage points to other direct costs, partly offset by positive forex impact and reversal of management bonus.

Operationally, some efficiency indicators improved despite the margin compression. Utilization (excluding trainees) increased to 85.1 percent from 84.3 percent. Voluntary attrition stayed low at 9.6 percent, marking the sixth consecutive quarter below 10 percent, as stated by management. Headcount increased to 11,342 from 10,779, with gross additions of 1,451 employees.

Accounts receivable days were stable to slightly better. Total DSO was 75 days in Q1 FY27 versus 78 days in Q4 FY26, with billed days at 48 and unbilled at 27.

AI narrative moves from messaging to deployments

Zensar’s management positioned AI as the central strategic theme for the year. The CEO said clients are shifting from modernization to AI native transformation, and the company launched ZenseAI AgentMesh during the quarter. It was described as a platform to discover, build, deploy and govern autonomous AI agents at scale, with an emphasis on governance and enterprise-grade controls.

The COO’s commentary added operational proof points. He said Zensar has productionized agent-based software development and testing across multiple global BFSI clients, delivering more than 25 percent productivity uplift. He also stated that 44 percent of code was AI generated and large-scale application migrations saw 50 to 60 percent acceleration. In addition, Zensar cited re-platforming of legacy estates including mainframe COBOL to modern architectures through agentic workflows, with 40 to 60 percent effort savings.

The company also highlighted multiple AI-linked wins, including AI-assisted grants management modernization, AI agent governance monitoring, and AI-native SAP modernization. While these are not quantified in revenue terms, they reinforce the company’s go-to-market focus on AI-led engineering and managed services.

Pipeline and near-term outlook: cautious tone with a large-deal ramp thesis

One point investors are likely to focus on is the order book. The Q1 FY27 snapshot shows an order book of $149.2 million, down 62.9 percent QoQ. Management tried to contextualize this. The CEO said Q1 is typically seasonally weak because renewals tend to occur in Q3 or Q4 depending on client financial year cycles. He also said the proportion of new business, including net new and new business from existing clients, is at an all-time high for Zensar.

On vertical outlook, the CEO was direct about mixed conditions. He expressed lower confidence on Europe and MCS in the current environment. He sounded more constructive on Africa and BFSI, and said HLS has recovered about 75 percent of a prior drop and should see growth in subsequent quarters.

On margins, the CFO provided a time-linked qualitative outlook. He said margins in Q2 and Q3 are expected to remain similar to Q1 levels as the company prioritizes ramp-up and growth, with improvement expected from Q3 onwards.

Capital allocation: cash supports optionality, including acquisitions

Zensar ended the quarter with cash and investments of $317.5 million. When asked about deploying this cash, the CEO said the company is not looking for small tuck-in acquisitions. Instead, it is evaluating scaled assets, indicating interest in targets with roughly$150 million to $200 million of revenue. He said Zensar is currently looking at two or three such assets.

Takeaways

Q1 FY27 reads like a setup quarter. Revenue growth was modest, but BFSI continued to gain share and delivered strong sequential growth. Profitability declined, but management gave a clear attribution to large deal transition and early-stage execution costs.

The next two quarters appear positioned as execution quarters. The company expects the large deal to ramp further in Q2, with the full revenue weight expected in Q3 and Q4. At the same time, the order book decline and weakness across non-BFSI verticals, especially TMT, remain the key items to watch alongside the company’s ability to convert its AI positioning into durable growth and margin recovery.